Ulrich Keilholz

Summary

Country: Germany

Publications

  1. ncbi A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS
    Ulrich Keilholz
    Department of Hematology and Oncology, Charite Campus Benjamin Franklin, Hindenburgdamm 30, Berlin, Germany
    Blood 113:6541-8. 2009
  2. ncbi Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group
    Ulrich Keilholz
    Department of Medicine III, Charite, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    J Clin Oncol 23:6747-55. 2005
  3. ncbi Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction
    Ulrich Keilholz
    Department of Medicine III, University Hospital Benjamin Franklin, Free University Berlin, Berlin, Germany
    Clin Cancer Res 10:1605-12. 2004
  4. ncbi Addition of GM-CSF to a peptide/KLH vaccine results in increased frequencies of CXCR3-expressing KLH-specific T cells
    Il Kang Na
    Department of Hematology, Oncology and Transfusion Medicine, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Cancer Immunol Immunother 56:391-6. 2007
  5. ncbi Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study)
    Alberto Fusi
    Charite Campus Benjamin Franklin, Berlin, Germany
    Eur J Cancer 45:3189-97. 2009
  6. ncbi Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1
    Anne Marie Asemissen
    Medizinische Klinik III, Hematology, Oncology, and Transfusion Medicine, , Berlin, Germany
    Clin Cancer Res 12:7476-82. 2006
  7. ncbi Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma
    Ronny Schuster
    Department of Medicine III Hematology, Oncology, and Transfusion Medicine, Charite, Campus Benjamin Franklin, Berlin, Germany
    Clin Cancer Res 13:1171-8. 2007
  8. ncbi Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104)
    Anne Marie Asemissen
    Medizinische Klinik III, , Onkologie und Transfusionsmedizin, , Berlin, Germany
    Clin Cancer Res 11:290-7. 2005
  9. ncbi Differences in T-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients
    Dirk Nagorsen
    Medizinische Klinik III, Hematology, Oncology, and Transfusion Medicine, University Hospital Benjamin Franklin, Berlin, Germany
    Int J Cancer 105:221-5. 2003
  10. ncbi Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma
    Antonia Busse
    Department of Medicine III Hematology and Oncology, Charite, Campus Benjamin Franklin, Berlin, Germany
    Eur J Cancer 47:690-6. 2011

Detail Information

Publications85

  1. ncbi A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS
    Ulrich Keilholz
    Department of Hematology and Oncology, Charite Campus Benjamin Franklin, Hindenburgdamm 30, Berlin, Germany
    Blood 113:6541-8. 2009
    ..18% at baseline and 0.41% in week 18. This WT1 vaccination study provides immunologic, molecular, and preliminary evidence of potential clinical efficacy in AML patients, warranting further investigations...
  2. ncbi Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group
    Ulrich Keilholz
    Department of Medicine III, Charite, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    J Clin Oncol 23:6747-55. 2005
    ..This study was performed to determine whether interleukin-2 (IL-2) as a component of chemoimmunotherapy influences survival of patients with metastatic melanoma...
  3. ncbi Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction
    Ulrich Keilholz
    Department of Medicine III, University Hospital Benjamin Franklin, Free University Berlin, Berlin, Germany
    Clin Cancer Res 10:1605-12. 2004
    ..Inconsistent reports on the detection of melanoma cells in peripheral blood by reverse transcriptase-PCR (RT-PCR) have resulted in uncertainty on the prognostic value of circulating melanoma cells...
  4. ncbi Addition of GM-CSF to a peptide/KLH vaccine results in increased frequencies of CXCR3-expressing KLH-specific T cells
    Il Kang Na
    Department of Hematology, Oncology and Transfusion Medicine, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Cancer Immunol Immunother 56:391-6. 2007
    ..These results show that CXCR3 expression on vaccine-induced T cells can be modulated by modifying the local vaccine milieu...
  5. ncbi Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study)
    Alberto Fusi
    Charite Campus Benjamin Franklin, Berlin, Germany
    Eur J Cancer 45:3189-97. 2009
    ....
  6. ncbi Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1
    Anne Marie Asemissen
    Medizinische Klinik III, Hematology, Oncology, and Transfusion Medicine, , Berlin, Germany
    Clin Cancer Res 12:7476-82. 2006
    ..CONCLUSION: In this study, a modified reverse immunology strategy was employed to identify a first immunogenic HLA-A*01-restricted T cell epitope of the tumor antigen WT1, which is of considerable interest for use in vaccination trials...
  7. ncbi Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma
    Ronny Schuster
    Department of Medicine III Hematology, Oncology, and Transfusion Medicine, Charite, Campus Benjamin Franklin, Berlin, Germany
    Clin Cancer Res 13:1171-8. 2007
    ..The aim of this study was to determine in patients with high-risk primary uveal melanoma whether the detection of circulating tumor cells by quantitative reverse transcription-PCR (RT-PCR) is of prognostic relevance...
  8. ncbi Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104)
    Anne Marie Asemissen
    Medizinische Klinik III, , Onkologie und Transfusionsmedizin, , Berlin, Germany
    Clin Cancer Res 11:290-7. 2005
    ..These effects are of relevance for tumor immunotherapy and provide a potential mechanism for the clinical efficacy of HDC added to IL-2...
  9. ncbi Differences in T-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients
    Dirk Nagorsen
    Medizinische Klinik III, Hematology, Oncology, and Transfusion Medicine, University Hospital Benjamin Franklin, Berlin, Germany
    Int J Cancer 105:221-5. 2003
    ..The findings reported here have implications for the development of antigen-specific T-cell therapies...
  10. ncbi Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma
    Antonia Busse
    Department of Medicine III Hematology and Oncology, Charite, Campus Benjamin Franklin, Berlin, Germany
    Eur J Cancer 47:690-6. 2011
    ..Therefore, we asked whether sorafenib had an influence on peripheral immune effector cells in a cohort of 35 mRCC patients receiving sorafenib treatment...
  11. ncbi "Wilms Tumor Protein 1" (WT1) peptide vaccination-induced complete remission in a patient with acute myeloid leukemia is accompanied by the emergence of a predominant T-cell clone both in blood and bone marrow
    Sebastian Ochsenreither
    Department of Hematology, Oncology, Charite Campus Benjamin Franklin, Berlin, Germany
    J Immunother 34:85-91. 2011
    ..At the time of relapse, the same clone reappeared spontaneously in PB but not in BM showing impaired functionality...
  12. ncbi Rational peptide-based tumour vaccine development and T cell monitoring
    Carmen Scheibenbogen
    Medizinische Klinik III, Hematology, Oncology, and Transfusion Medicine, Charite, Campus Benjamin Franklin, Free and Humbold University, Berlin, Germany
    Semin Cancer Biol 13:423-9. 2003
    ..There is accumulating evidence from clinical cancer vaccination trials of a relation between the induction of specific T cells and clinical efficacy...
  13. ncbi Immunological monitoring of cancer vaccine therapy
    Dirk Nagorsen
    Charite, Campus Benjamin Franklin, Medizinische Klinik III, Hindenburgdamm 30, 12200 Berlin, Germany
    Expert Opin Biol Ther 4:1677-84. 2004
    ....
  14. ncbi Identification of truncated chemokine receptor 7 in human colorectal cancer unable to localize to the cell surface and unreactive to external ligands
    Il Kang Na
    Hematology, Oncology and Transfusion Medicine, Charite CBF, Hindenburgdamm 30, Berlin, Germany
    Int J Cancer 123:1565-72. 2008
    ..Further studies would be necessary to identify a potential intracellular role of the truncated CCR7, abundantly present in the cytoplasm...
  15. ncbi Long term presence of a single predominant tyrosinase-specific T-cell clone associated with disease control in a patient with metastatic melanoma
    Sebastian Ochsenreither
    Department of Hematology and Oncology, Charite Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Int J Cancer 126:2497-502. 2010
    ....
  16. ncbi CMV-specific central memory T cells reside in bone marrow
    Anne Letsch
    Department of Hematology, Oncology, Charite, Berlin, Germany
    Eur J Immunol 37:3063-8. 2007
    ..CMV specific BM-derived T(CM) might be a valuable source for generating T cells for adoptive transfer...
  17. ncbi Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine
    Zhian Liu
    Department of Hematology and Medical Oncology, Charite, Berlin, Germany
    Cancer Biol Ther 10:860-4. 2010
    ..Although a proof for the clinical significance of EGFR-positive circulating tumor cells is currently lacking, expression of EGFR may predict response to lapatinib-based treatments as in the case presented...
  18. ncbi A two-cohort phase II clinical trial of gemcitabine plus treosulfan in patients with metastatic uveal melanoma
    Alexander Schmittel
    Department of Internal Medicine III Haematology, Oncology and Transfusion Medicine, Charite Campus Benjamin Franklin, Berlin, Germany
    Melanoma Res 15:447-51. 2005
    ..1% versus 47.3%, respectively. Based on the observation of prolonged disease stabilization, we recommend further investigation of the gemcitabine/treosulfan combination with a dose of 3500 mg/m2 of treosulfan in metastatic uveal melanoma...
  19. ncbi Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma
    Alexander Schmittel
    Department of Internal Medicine III Haematology, Oncology and Transfusion Medicine, Charite, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Melanoma Res 15:205-7. 2005
    ..9-13.8). Grade 3 and 4 thrombopenia and leucopenia occurred in eight and nine of the 19 patients, respectively. The addition of cisplatin to the GeT regimen results in excessive haematological toxicity without improvement in efficacy...
  20. ncbi Systemic immune tuning in renal cell carcinoma: favorable prognostic impact of TGF-?1 mRNA expression in peripheral blood mononuclear cells
    Antonia Busse
    Department of Medicine III Hematology and Oncology, Charite, Campus Benjamin Franklin, Berlin, Germany
    J Immunother 34:113-9. 2011
    ..The positive prognostic influence of high TGF-?1 mRNA expression levels may reflect immune promoting functions of TGF-? in combined activity with inflammatory cytokines...
  21. ncbi Chemokine receptor CCR6 expression level and aggressiveness of prostate cancer
    Pirus Ghadjar
    Department of Hematology, Medical Oncology and Transfusion Medicine, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200, Berlin, Germany
    J Cancer Res Clin Oncol 134:1181-9. 2008
    ..This study was performed to investigate a potential relationship between CCR6 and CCL20 expression and features of human prostate cancer (PCA) at time of primary treatment...
  22. ncbi Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib
    Kaja Zimmermann
    Department of Medicine III Hematology, Oncology and Transfusion Medicine, Charite, Campus Benjamin Franklin, Berlin, Germany
    Oncology 76:350-4. 2009
    ..It was unclear whether the similarities of the two drugs would lead to complete cross-resistance, or whether sequential application would be efficacious...
  23. ncbi Expression of the stem cell markers nestin and CD133 on circulating melanoma cells
    Alberto Fusi
    Department of Hematology and Medical Oncology, Charite, Campus Benjamin Franklin, Berlin, Germany
    J Invest Dermatol 131:487-94. 2011
    ..These findings show that CMCs expressed stem cell-associated markers NES and CD133. Higher expression of NES on CMCs might represent an index of poor prognosis...
  24. ncbi Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination
    Antonia Busse
    Charite CBF, Department of Medicine III, Berlin, Germany
    J Transl Med 8:5. 2010
    ..Here, we analyzed 10 HLA-A2 positive patients with acute myeloid leukemia (AML) for loss or mutations of the WT1 epitope or epitope flanking sequences that may abolish proper T cell recognition or epitope presentation...
  25. ncbi Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome
    Ronny Schuster
    Department of Hematology and Oncology, Campus Benjamin Franklin, Hindenburgdamm, Berlin, Germany
    Melanoma Res 20:191-6. 2010
    ..TACE is well tolerated and effective in pretreated patients with liver metastases from uveal melanoma. TACE should further be evaluated as first-line therapy in prospective randomized clinical trials...
  26. ncbi Long-term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides
    Carmen Scheibenbogen
    Medizinische Klinik III, , Onkologie und Transfusionsmedizin, , , Berlin, Germany
    Int J Cancer 99:403-8. 2002
    ..These results suggest that peptide vaccination resulted in a prolonged relapse-free interval in these high-risk patients...
  27. ncbi Malignant melanoma--clinical development of peptide-based melanoma vaccines
    Alexander Schmittel
    Medizinische Klinik III, Hematology, Oncology, and Transfusion Medicine, Charit, Campus Benjamin Franklin, Berlin, Germany
    Front Radiat Ther Oncol 39:171-80. 2006
  28. ncbi Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides
    Carmen Scheibenbogen
    Medizinische Klinik III, Haematologie, Onkologie und Transfusionsmedizin, , , Berlin, Germany
    Int J Cancer 104:188-94. 2003
    ..The combined application of GM-CSF and KLH was associated with early induction of T-cell responses...
  29. ncbi Production of bifunctional single-chain antibody-based fusion proteins in Pichia pastoris supernatants
    Hossein Panjideh
    Medizinische Klinik III, Hematology, Oncology und Transfusion Medicine, Charite, Campus Benjamin Franklin, Hindenburgdamm 30, 12200, Berlin, Germany
    Bioprocess Biosyst Eng 31:559-68. 2008
    ..Our results demonstrate the suitability of methylotrophic Pichia expression systems and laboratory-scale bioreactors for the production of high quantities of bifunctionally active heterologous single-chain fusion proteins...
  30. ncbi Surface expression of gpA33 is dependent on culture density and cell-cycle phase and is regulated by intracellular traffic rather than gene transcription
    Dietmar Frey
    Centrum für Tumormedizin, Charite Universitatsmedizin Berlin, Berlin, Germany
    Cancer Biother Radiopharm 23:65-73. 2008
    ..However, intracellular traffic and recycling to the cell surface appear to play a major role in its function and to have an influence on its surface density superseding translational regulation...
  31. ncbi Wilms' tumor gene 1 (WT1) expression in subtypes of acute lymphoblastic leukemia (ALL) of adults and impact on clinical outcome
    Antonia Busse
    Department of Medicine III, Charite, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Hematol 88:1199-205. 2009
    ..Cox regression analysis, considering ALL phenotype as well as molecular-cytogenetic subsets, revealed no independent prognostic role of WT1 expression level for disease-free and overall survival...
  32. ncbi Nuclear expression of CXCR4 in tumor cells of non-small cell lung cancer is correlated with lymph node metastasis
    Il Kang Na
    Department of Medicine III, Hematology, Oncology and Transfusion Medicine, Charite, Campus Benjamin Franklin, Berlin, D 12200 Berlin, Germany
    Hum Pathol 39:1751-5. 2008
    ..The association between aberrant expression of CXCR4 in the nucleus of non-small cell lung cancer and metastasis to lymph nodes points toward a potential tumor metastasis promoting function of nuclear CXCR4...
  33. ncbi Randomized phase II study of paclitaxel and carboplatin or vinorelbine in advanced non-small cell lung cancer
    Kristoph Jahnke
    Department of Hematology and Oncology, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    Anticancer Res 31:317-23. 2011
    ..A randomized phase II trial was conducted to determine if two non-platinum protocols are able to yield a similar efficacy and toxicity profile as compared to two platinum-based doublets in advanced non-small cell lung cancer (NSCLC)...
  34. ncbi Expression of Wilms' tumor gene 1 at different stages of acute myeloid leukemia and analysis of its major splice variants
    Jan M Siehl
    Med Klinik III Hematology, Oncology and Transfusion Medicine, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Hematol 83:745-50. 2004
    ..Together, these findings support the potential of WT1 as a target for novel treatment approaches in AML...
  35. ncbi CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia
    Carmen Scheibenbogen
    Medizinische Klinik III, Hämatologie, Onkologie und Transfusionsmedizin, Universitatsklinikum Benjamin Franklin, Freie Universitat Berlin, Hindenburgdamm 30, 12200 Berlin, Germany
    Blood 100:2132-7. 2002
    ..These data therefore support the immunogenicity of WT1 and proteinase 3 in acute leukemia patients and the potential usefulness of these antigens for leukemia vaccines...
  36. ncbi Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients
    Alexander Schmittel
    Medizinische Klinik III Hämatologie, Onkologie und Transfusionsmedizin, Charite Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Lung Cancer 55:109-13. 2007
    ..The efficacy and toxicity of bendamustine chemotherapy in relapsed small cell lung cancer (SCLC) was determined in this phase II trial...
  37. ncbi Quantitative real-time RT-PCR for detection of disseminated tumor cells in peripheral blood of patients with colorectal cancer using different mRNA markers
    Ronny Schuster
    Department of Medicine III, University Hospital Benjamin Franklin, Free University Berlin, Berlin, Germany
    Int J Cancer 108:219-27. 2004
    ..We conclude that either copy numbers of analyzed markers in circulating tumor cells are not sufficient for detection or, more probably, peripheral blood is not a suitable compartment for detection of tumor cells in colorectal cancer...
  38. ncbi Specific central memory T cells in the bone marrow of patients immunized against tyrosinase peptides
    Anne Letsch
    Department of Hematology, Oncology, and Transfusion Medicine, Charit, Campus Benjamin Franklin, Berlin, Germany
    J Immunother (1997) 29:201-7. 2006
    ..This study suggests that peptide vaccination can generate a fully functional memory T-cell response characterized by central and effector memory phenotypes, proliferative potential, and BM tropism...
  39. ncbi Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study
    Jan M Siehl
    Medizinische Klinik III, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Cancer 104:611-7. 2005
    ..To improve the tolerability and potential efficacy of this combination, the authors combined a moderate dose of continuous infusion ifosfamide with liposomal daunorubicin (L-Dauno)...
  40. ncbi Functional CCR9 expression is associated with small intestinal metastasis
    Anne Letsch
    Charite University Medicine Berlin, Campus Benjamin Franklin, Hematology, Oncology and Transfusion Medicine, Berlin, Germany
    J Invest Dermatol 122:685-90. 2004
    ..The regulation of receptor function seems to be a critical step in the metastatic process...
  41. ncbi Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits
    Antonia Busse
    Department of Medicine III Hematology, Oncology, and Transfusion Medicine, Charite, Campus Benjamin Franklin, Berlin, Germany
    Cancer 112:659-70. 2008
    ..This study was undertaken to investigate the sensitivity of neoplastic B cells and solid tumor cells to proteasome inhibition with respect to constitutive expression levels of proteasome subunits...
  42. ncbi Extrapulmonary small cell carcinoma (EPSCC): 10 years' multi-disciplinary experience at Charité
    Sebastian Ochsenreither
    Charite, Campus Benjamin Franklin, Department of Medicine III Hematology and Oncology, Hindenburgdamm 30, 12200 Berlin, Germany
    Anticancer Res 29:3411-5. 2009
    ..Extrapulmonary small cell carcinoma (EPSCC) is a rare disease of highly proliferating neuroendocrine tumor cells. Therapy and outcome of EPSCC patients treated at our institution were retrospectively analyzed...
  43. ncbi Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients
    Zhian Liu
    Department of Hematology and Medical Oncology, Charite, Berlin, Germany
    J Transl Med 9:70. 2011
    ..We optimized a method for enrichment, subsequent detection and characterization of CTCs based on depletion of the leukocyte fraction...
  44. ncbi A phase II study of bendamustine chemotherapy as second-line treatment in metastatic uveal melanoma
    Martin Schmidt-Hieber
    Medizinische Klinik III (Haematology, Oncology and Transfusion Medicine, University Medicine Berlin, , Berlin, Germany
    Melanoma Res 14:439-42. 2004
    ..According to Response Evaluation Criteria in Solid Tumours (RECIST), all patients showed progressive disease. We conclude that bendamustine is ineffective as second-line chemotherapy for metastatic uveal melanoma...
  45. ncbi Antigen-specific cancer vaccines
    Ulrich Keilholz
    Department of Medicine III, Charite Campus Benjamin Franklin, Berlin, Germany
    Recent Results Cancer Res 176:213-8. 2007
    ....
  46. ncbi Relative quantification of TCR Vbeta-chain families by real time PCR for identification of clonal T-cell populations
    Sebastian Ochsenreither
    University Hospital Benjamin Franklin, Medizinische Klinik III, Hematology, Oncology, and Transfusion Medicine, Charite Universitatsmedizin Berlin, 12200, Berlin, Germany
    J Transl Med 6:34. 2008
    ..Here, the heterogeneity of sequences within single families is the most challenging problem for exact quantification...
  47. ncbi Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment
    Konrad Klinghammer
    Department of Hematology and Oncology, Campus Benjamin Franklin and Laboratory for Translational Radiobiology and Radiooncology, Charite Universitatsmedizin Berlin, Berlin, Germany
    Clin Cancer Res 16:304-10. 2010
    ..In this study, we analyzed whether cetuximab-induced skin rash was correlated with distinct polymorphisms within the EGFR gene known to modulate EGFR expression, ligand binding, or signaling activity...
  48. ncbi Bone marrow contains melanoma-reactive CD8+ effector T cells and, compared with peripheral blood, enriched numbers of melanoma-reactive CD8+ memory T cells
    Anne Letsch
    University Hospital Benjamin-Franklin, Medizinische Klinik III, Hematology, Oncology, Free University of Berlin, 12200 Berlin, Germany
    Cancer Res 63:5582-6. 2003
    ..Thus, the BM may be an important compartment for tumor surveillance harboring a tumor-specific memory T-cell pool in addition to effector T cells...
  49. ncbi Comparison of T-cell receptor repertoire restriction in blood and tumor tissue of colorectal cancer patients
    Sebastian Ochsenreither
    Charite, Campus Benjamin Franklin, Department of Hematology and Oncology, Hindenburgdamm 30, 12200 Berlin, Germany
    J Transl Med 8:35. 2010
    ....
  50. ncbi Biochemotherapy of melanoma
    Ulrich Keilholz
    Department of Medicine III (Hematology, Oncology and Transfusion Medicine, Charit, Campus Benjamin Franklin, Free University Berlin, Germany
    Forum (Genova) 13:158-65; quiz 189. 2003
    ..Therefore current trials are under way trying to improve the efficacy of immunotherapy alone by adding histamine or vaccines to IL-2...
  51. ncbi An intron 9 containing splice variant of PAX2
    Antonia Busse
    Department of Medicine III, Charite, Campus Benjamin Franklin, Berlin, Germany
    J Transl Med 7:36. 2009
    ..However, PAX2 expression was frequently identified in neoplasia responsible for the growth and survival of cancer cells. Due to alternative splicing of exon 6, exon 10 and exon 12 four isoforms of PAX2 are described so far...
  52. ncbi A clinical phase I trial of gemcitabine and treosulfan in uveal melanoma and other solid tumours
    Ulrich Keilholz
    Department of Medicine III Hematology, Oncology and Transfusion Medicine, Free University Berlin, Charite Campus Benjamin Franklin, Hindenburgdamm 30, 12200, Germany
    Eur J Cancer 40:2047-52. 2004
    ..In the uveal melanoma patients, one partial response (PR) and 15 stablisations of disease (SD) were recorded and whether this translates into a survival gain should be explored further...
  53. ncbi Independent prognostic factors for distant metastases and survival in patients with primary uveal melanoma
    Alexander Schmittel
    Department of Medicine III Hematology, Oncology and Transfusionmedicine, Charite, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Eur J Cancer 40:2389-95. 2004
    ..9, P<0.001) within the first 3 years. This study determined patients with ciliary body involvement to be candidates for future adjuvant therapeutic interventions...
  54. ncbi Immune monitoring of T-cell responses in cancer vaccine development
    Ulrich Keilholz
    Charite, Campus Benjamin Franklin, Department of Medicine III, Free University Berlin, Germany
    Clin Cancer Res 12:2346s-2352s. 2006
    ....
  55. ncbi Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3? sequence associated with remission in one patient is detectable in other vaccinated patients
    Sebastian Ochsenreither
    Department of Hematology and Oncology, Charite Campus Benjamin Franklin, Hindenburgdamm 30, 12200, Berlin, Germany
    Cancer Immunol Immunother 61:313-22. 2012
    ..In this study, we address the question of whether this predominant clone or the accompanying V?11 restriction could be found in other AML patients vaccinated with the same WT1 peptide...
  56. ncbi Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer
    Pirus Ghadjar
    Department of Hematology, Institute for Medical Informatics, Biometry, and Clinical Epidemiology, Charite, Campus Benjamin Franklin, Berlin, Germany
    J Clin Oncol 24:1910-6. 2006
    ..Chemokine receptor CCR6 is expressed on a subset of T cells and is associated with their migration into the liver. This study was performed to analyze a possible association between CCR6 expressed by primary CRC and liver metastases...
  57. ncbi A phase I/IIa clinical trial of CLAOP21 and CLAOP14 in patients with high grade non-Hodgkins lymphoma
    Antonia Busse
    Department of Medicine III, Charite, Campus Benjamin Franklin, Berlin, Germany
    Leuk Lymphoma 48:1755-63. 2007
    ..Both regimens were active with an overall response rate of 60% and 77%, respectively. The recommended dose of pegliposomal doxorubicin in the biweekly regimen for Phase II/III testing is 20 mg/m(2)...
  58. ncbi Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment
    Carmen Scheibenbogen
    Medizinische Klinik III, Hematology, Oncology and Transfusion Medicine, Universitaetsklinikum Benjamin Franklin, Freie Universitat Berlin, Berlin, Germany
    Int J Cancer 98:409-14. 2002
    ....
  59. ncbi Possible regulation of Wilms' tumour gene 1 (WT1) expression by the paired box genes PAX2 and PAX8 and by the haematopoietic transcription factor GATA-1 in human acute myeloid leukaemias
    Jan M Siehl
    Medizinische Klinik III Haematology, Oncology and Transfusion Medicine, Universitatsklinikum Benjamin Franklin, Freie Universitat, Berlin, Germany
    Br J Haematol 123:235-42. 2003
    ..In two-thirds of leukaemias from our series, the basis of WT1 upregulation cannot be explained by the simple upregulation of the known WT1 activators...
  60. ncbi Design, construction, and in vitro analysis of A33scFv::CDy, a recombinant fusion protein for antibody-directed enzyme prodrug therapy in colon cancer
    Vania Coelho
    CharitéCentrum fur Tumormedizin, Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie CBF, 12200 Berlin, Germany
    Int J Oncol 31:951-7. 2007
    ..These results demonstrate bifunctional activity of the heterogeneous Pichia-produced A33scFv::CDy fusion protein and proof of principle for the ADEPT system proposed herein...
  61. ncbi Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia
    Sandra Heesch
    Department of Hematology and Oncology, Charite, University Hospital Berlin, Campus Benjamin Franklin, Hindenburgdamm 30 12203 Berlin, Germany
    Haematologica 95:942-9. 2010
    ..No larger studies have performed a combined approach including WT1 mutation and expression analyses in acute T-lymphoblastic leukemia...
  62. ncbi Phase II trial of carboplatin, paclitaxel plus vinorelbine in non-small cell lung cancer patients
    Alexander Schmittel
    Department of Medicine III Hematology, Oncology and Transfusionmedicine, University Medicine of Berlin, Charite, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Anticancer Res 25:1333-6. 2005
    ..Vinorelbine was added to carboplatin plus paclitaxel to determine efficacy and toxicity in non-small cell lung cancer (NSCLC) patients with good performance status...
  63. ncbi Quantitative nested real-time RT-PCR specific for tyrosinase transcripts to quantitate minimal residual disease
    Nicole Max
    Department of Medicine III, University Hospital Benjamin Franklin, Free University Berlin, Hindenburgdamm 30, 12200, Berlin, Germany
    Clin Chim Acta 317:39-46. 2002
    ....
  64. ncbi Biochemotherapy for advanced melanoma
    Ulrich Keilholz
    Department of Medicine III (Hematology, Oncology, and Transfusion Medicine, University Hospital Benjamin Franklin, Free University of Berlin, Berlin, Germany
    Semin Oncol 29:456-61. 2002
    ..So far, none of the approaches has been proven to confer a survival benefit and thus the uniform desire is to include as many patients as possible in controlled clinical trials...
  65. ncbi Spinal paraparesis due to leukemic meningitis in early-stage chronic lymphocytic leukemia
    Martin Schmidt-Hieber
    Medizinische Klinik III, , Hindenburgdamm 30, D-12200, Berlin, Germany
    Leuk Lymphoma 46:619-21. 2005
    ..Leukemic meningitis is a rare manifestation of CLL, especially in early stages. Selective spinal paraparesis as the first symptom of meningitis in CLL is even rarer and has been reported only once...
  66. ncbi Restricted T-cell receptor repertoire in melanoma metastases regressing after cytokine therapy
    Martina Willhauck
    Medizinische Klinik und Poliklinik V, Hospitalstrasse 3, 69115 Heidelberg, Germany
    Cancer Res 63:3483-5. 2003
    ..This finding indicates that the T-cell response in regressing melanoma lesions is dominated by T cells directed toward a limited number of epitopes and that epitope-specific T cells frequently use a highly restricted TCR repertoire...
  67. ncbi Molecular staging in stage II and III melanoma patients and its effect on long-term survival
    Christiane Voit
    Department of Dermatology of the Charite, Humboldt University, Schumannstr 20 21, 10117 Berlin, Germany
    J Clin Oncol 23:1218-27. 2005
    ..To assess the prognostic value of serial reverse transcriptase polymerase chain reaction (RT-PCR) -based measurements of tyrosinase mRNA in peripheral blood of stage II and III melanoma patients...
  68. ncbi Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity
    Danila Valmori
    Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, University Hospital, 1005 Lausanne, Switzerland
    Cancer Res 62:1743-50. 2002
    ..Overall, these results provide the first evidence that a proportion of melanoma patients have circulating tumor-reactive T cells, which are lytic effectors cells...
  69. ncbi Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2
    Robert Godal
    Department of Internal Medicine, St Elizabeth Oncological Institute, Bratislava, Slovakia
    Blood 107:3205-11. 2006
    ..These results show that resistance to perforin-dependent pathways is not a relevant immune escape mechanism in lymphoma and therefore is unlikely to impair clinical outcome of immunotherapeutic approaches...
  70. ncbi Peptide vaccination after repeated resection of metastases can induce a prolonged relapse-free interval in melanoma patients
    Anne Letsch
    Hematology, Oncology and Transfusion Medicine, Medizinische Klinik III, , D-12200 Berlin, Germany
    Int J Cancer 114:936-41. 2005
    ..In conclusion, adjuvant peptide vaccination was associated with cessation of recurrences in 4 of 9 patients, of whom all 4 had an immunologic response to the vaccine...
  71. ncbi Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial
    Henrik Schmidt
    Department of Oncology, Aarhus University Hospital, Aarhus C, Denmark
    J Clin Oncol 25:1562-9. 2007
    ..In this study, we aimed to validate this finding in a large cohort of stage IV melanoma patients...
  72. ncbi Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma
    Bruce Elliott
    Royal Surrey County Hospital Guildford, Guildford, United Kingdom
    Clin Cancer Res 13:3825-30. 2007
    ..The aim of this study was to investigate the prognostic importance of the maximal density of mature DCs in SLNs...
  73. ncbi Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma
    Claus Garbe
    University Department of Dermatology, Tubingen, Germany
    Melanoma Res 17:393-9. 2007
    ..Additionally, in the stage of regional metastasis, whole body imaging should be performed every 6 months; in the stage of distant metastasis, surveillance has to be scheduled individually...
  74. ncbi Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer
    Christian Peschel
    Technische Universitat, III Medizinische Klinik, Munchen, Germany
    Lung Cancer 60:374-80. 2008
    ..v. infusion at a dose of 5mg/m(2), every 2 weeks, to patients with chemotherapy pretreated advanced non-small cell lung cancer (NSCLC)...
  75. ncbi Specific tumour localisation of a huA33 antibody--carboxypeptidase A conjugate and activation of methotrexate-phenylalanine
    P Markus Deckert
    Medizinische Klinik III Haematology, Oncology and Transfusion Medicine, Charite Campus Benjamin Franklin, D 12200 Berlin, Germany
    Int J Oncol 24:1289-95. 2004
    ..In summary, our results demonstrate in principle the feasibility of A33-based enzyme targeting, but they call for small recombinant antibody-enzyme constructs to facilitate tumour penetration and clearance from the bloodstream...
  76. ncbi Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
    Alexander M M Eggermont
    Erasmus University Medical Center, Rotterdam, Netherlands
    Lancet 372:117-26. 2008
    ..Any benefit of adjuvant interferon alfa-2b for melanoma could depend on dose and duration of treatment. Our aim was to determine whether pegylated interferon alfa-2b can facilitate prolonged exposure while maintaining tolerability...
  77. ncbi Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting
    Claus Garbe
    University Department of Dermatology, Tubingen, Germany
    Melanoma Res 18:152-60. 2008
    ..An urgent need for development of new treatment modalities is necessary and general principles of experimental immunotherapy are outlined...
  78. ncbi Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial
    Alexander M M Eggermont
    Department of Surgical Oncology, Erasmus University Medical Centre Daniel den Hoed Cancer Centre, 3008 AE Rotterdam, Netherlands
    Lancet 366:1189-96. 2005
    ..Our aim was, therefore, to assess the effect of two regimens of interferon of intermediate dose versus observation alone on distant metastasis-free interval (DMFI) and overall survival in such patients...
  79. ncbi A monoclonal melanoma-specific T-cell population phenotypically indistinguishable from CD3+ LGL-leukemia
    Danila Valmori
    Blood 101:4643-4. 2003
  80. ncbi Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma
    Claus Garbe
    University Department of Dermatology, Tubingen, Germany
    Melanoma Res 18:61-7. 2008
    ..In distant metastases, radiation therapy is particularly indicated in bone metastases, brain metastases and soft tissue metastases...
  81. ncbi Innovations and challenges in melanoma: summary statement from the first Cambridge conference
    Michael B Atkins
    Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 12:2291s-2296s. 2006
    Innovations and Challenges in Melanoma, chaired by Michael Atkins and cochaired by Ulrich Keilholz, John Kirkwood, and Jeffrey Sosman, was held July 15 to 16, 2005, in Cambridge, Massachusetts...
  82. ncbi Expression of the chemokine receptors CXCR4, CXCR5, and CCR7 in primary central nervous system lymphoma
    Kristoph Jahnke
    Blood 106:384-5. 2005
  83. ncbi Circulating tumor cells: the 'leukemic phase' of solid cancers
    Simone Mocellin
    Department of Oncological and Surgical Sciences, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
    Trends Mol Med 12:130-9. 2006
    ..This would provide a formidable tool for prognosis evaluation, anticancer-drug development and, ultimately, cancer-therapy personalization...
  84. ncbi [Brief guidelines: malignant melanoma of the skin]
    Claus Garbe

    J Dtsch Dermatol Ges 4:344-9. 2006